A clinical study demonstrated that using an anti-EGFRvIII-CAR in patients with glioblastoma, resulted in antigen loss and downregulation of the EGFR/EGFRvIII receptor appeared to promote T-cell resistance [47]. The gene discussed is EGFR; the disease is glioblastoma.